Malignant Neoplasms of Digestive Organs
9
1
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
Selumetinib and Olaparib in Solid Tumors
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
CART Therapy in GUCY2C-positive Digestive Tract Tumors
Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
CART Therapy in Digestive System Tumors
Neuromuscular Blockade on Shoulder Pain of Elderly
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies